<DOC>
	<DOCNO>NCT00711646</DOCNO>
	<brief_summary>The purpose study evaluate efficacy , safety tolerability Sativex® subject diagnose MS spasticity .</brief_summary>
	<brief_title>A Study Sativex® Relief Spasticity Subjects With Multiple Sclerosis .</brief_title>
	<detailed_description>This eight week ( two week baseline , six week treatment ) , multicentre , double blind , randomise , placebo control parallel group study evaluate efficacy , safety tolerability Sativex® subject diagnose MS spasticity . Subjects screen determine eligibility complete two week baseline period . Subjects return site assessment , randomisation dose introduction . Visits occur end treatment week two end study ( treatment week six ) withdrawal .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Muscle Spasticity</mesh_term>
	<criteria>Willing able give inform consent . Male female , age 18 year . Stable disease least three month prior study entry , opinion investigator . Diagnosed MS whose spasticity wholly relieve therapy time study entry . Significant spasticity least two muscle group define score two Ashworth Scale muscle group . Stable dose current antispasticity medication least 30 day prior study entry . Willing maintain stable dose antispasticity medication level physiotherapy duration study . Clinically acceptable laboratory result Visit 2 . Willing , female child bear potential male subject partner child bear potential , ensure effective contraception use study three month thereafter . No cannabinoid use ( cannabis , Marinol® Nabilone ) least seven day Visit 1 willing abstain use cannabis study . Able ( investigator opinion ) willing comply study requirement . Willing Home Office notify participation study ( applicable UK centre ) . Willing allow GP consultant , appropriate , notified participation study . History schizophrenia , psychotic illness , severe personality disorder significant psychiatric disorder depression associate underlying condition . Known history alcohol substance abuse . Severe cardiovascular disorder , ischaemic heart disease , arrhythmia , poorly control hypertension severe heart failure . History epilepsy . Female subject pregnant , lactate plan pregnancy course study . Significant renal hepatic impairment . Scheduled elective surgery procedure require general anaesthesia study . Subject terminally ill inappropriate placebo medication . Any significant disease disorder , opinion investigator , either put subject risk participation study , influence result study , subject 's ability participate study . Regular levodopa ( Sinemet® , Sinemet Plus® , Levodopa , Ldopa , Madopar® , Benserazide ) therapy within seven day study entry . Male subject receive sildenafil ( Viagra® ) unwilling stop medication duration study . Subjects take fentanyl ( Durogesic® , Actiq® ) Subjects take antiarrhythmic medication . Known suspect hypersensitivity cannabinoids excipients study medication . Known suspect adverse reaction cannabinoids . Planned travel outside UK study ( applicable UK centre ) . Donation blood study . Subjects participate another research study 12 week prior study entry . Subjects previously randomise study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Spasticity</keyword>
	<keyword>Multiple Sclerosis</keyword>
</DOC>